Posterior Cingulate Lactate as a Metabolic Biomarker in Amnestic Mild Cognitive Impairment

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Weaver, Kurt E ^a,b   Richards, Todd L ^a,b   Logsdon, Rebecca G ^b   McGough, Ellen L ^a   Minoshima, Satoshi ^a   Aylward, Elizabeth H ^c   Kleinhans, Natalia M ^a,b   Grabowski, Thomas J ^a,b   McCurry, Susan M ^b   Teri, Linda ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ANGULAR GYRUS; ARTICLE; BRAIN METABOLISM; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE METABOLISM; GRAY MATTER; HIPPOCAMPUS; HUMAN; INFERIOR TEMPORAL GYRUS; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL CORTEX; ORBITAL CORTEX; PARAHIPPOCAMPAL GYRUS; POSTERIOR CINGULATE; STROOP TEST; SUPERIOR TEMPORAL SULCUS; THALAMUS; VERY ELDERLY; WECHSLER MEMORY SCALE; AMNESIA; CINGULATE GYRUS; COGNITIVE DYSFUNCTION; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES;

AGED; AGED, 80 AND OVER; AMNESIA; BIOMARKERS; COGNITIVE DYSFUNCTION; FEMALE; GYRUS CINGULI; HUMANS; LACTIC ACID; MAGNETIC RESONANCE IMAGING; MALE;

EID: 84941649546     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/610605     Document Type: Article

References (59)

1. L. Mosconi, A. Pupi, and M. J. de Leon, "Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease," Annals of the New York Academy of Sciences, vol. 1147, pp. 180-195, 2008.
2. G. Chételat, B. Desgranges, V. de la Sayette et al., "Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment," Brain, vol. 126, no. 9, pp. 1955-1967, 2003.
3. S. Yamaguchi, K. Meguro, M. Itoh et al., "Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer's disease as shown by MRI and PET," Journal of Neurology, Neurosurgery and Psychiatry, vol. 62, no. 6, pp. 596-600, 1997.
4. L. L. Beason-Held, "Dementia and the default mode," Current Alzheimer Research, vol. 8, no. 4, pp. 361-365, 2011.
5. L.Wang, P. LaViolette, K. O'Keefe et al., "Intrinsic connectivity between the hippocampus and posteromedial cortex predicts memory performance in cognitively intact older individuals," NeuroImage, vol. 51, no. 2, pp. 910-917, 2010.
6. C. Sestieri, M. Corbetta, G. L. Romani, and G. L. Shulman, "Episodic memory retrieval, parietal cortex, and the default mode network: functional and topographic analyses," Journal of Neuroscience, vol. 31, no. 12, pp. 4407-4420, 2011.
7. E. M. Reiman, "Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments," Neurobiology of Aging, vol. 32, supplement 1, pp. S44-S47, 2011.
8. V. T. Marchesi, "Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy," The FASEB Journal, vol. 25, no. 1, pp. 5-13, 2011.
9. A.-L. Lin and D. L. Rothman, "What have novel imaging techniques revealed about metabolism in the aging brain?" Future Neurology, vol. 9, no. 3, pp. 341-354, 2014.
10. C. Iadecola, "Neurovascular regulation in the normal brain and in Alzheimer's disease," Nature Reviews Neuroscience, vol. 5, no. 5, pp. 347-360, 2004.
11. W. Dai, O. L. Lopez, O. T. Carmichael, J. T. Becker, L. H. Kuller, and H. M. Gach, "Mild cognitive impairment and Alzheimer disease: patterns of altered cerebral blood flow atMR imaging," Radiology, vol. 250, no. 3, pp. 856-866, 2009.
12. M. J. Mcmanus, M. P. Murphy, and J. L. Franklin, "The mitochondria-targeted antioxidant mitoq prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease," Journal of Neuroscience, vol. 31, no. 44, pp. 15703-15715, 2011.
13. P. H. Reddy, R. Tripathi, Q. Troung et al., "Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics," Biochimica et Biophysica Acta, vol. 1822, no. 5, pp. 639-649, 2012.
14. P. E. Sijens, G. P. A. Smit, L. A. Rödiger et al., "MR spectroscopy of the brain in Leigh syndrome," Brain and Development, vol. 30, no. 9, pp. 579-583, 2008.
15. R. P. Saneto, S. D. Friedman, and D.W. Shaw, "Neuroimaging of mitochondrial disease," Mitochondrion, vol. 8, no. 5-6, pp. 396-413, 2008.
16. A. Schurr, "Lactate: the ultimate cerebral oxidative energy substrate?" Journal of Cerebral Blood Flow & Metabolism, vol. 26, no. 1, pp. 142-152, 2006.
17. A. Almeida, J. Almeida, J. P. Bolaños, and S. Moncada, "Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 26, pp. 15294-15299, 2001.
18. C. Berthet, H. Lei, J. Thevenet, R. Gruetter, P. J.Magistretti, and L.Hirt, "Neuroprotective role of lactate after cerebral ischemia," Journal of Cerebral Blood Flow and Metabolism, vol. 29, no. 11, pp. 1780-1789, 2009.
19. D. D. M. Lin, T. O. Crawford, and P. B. Barker, "Proton MR spectroscopy in the diagnostic evaluation of suspected mitochondrial disease," American Journal of Neuroradiology, vol. 24, no. 1, pp. 33-41, 2003.
20. E. B. Cady, "Magnetic resonance spectroscopy in neonatal hypoxic-ishaemic insults," Child's Nervous System, vol. 17, no. 3, pp. 145-149, 2001.
21. G. Stoppe, H. Bruhn, P. J. W. Pouwels, W. Hänicke, and J. Frahm, "Alzheimer disease: absolute quantification of cerebral metabolites in vivo using localized proton magnetic resonance spectroscopy," Alzheimer Disease and Associated Disorders, vol. 14, no. 2, pp. 112-119, 2000.
22. T. Ernst, L. Chang, R. Melchor, and C. M. Mehringer, "Frontotemporal dementia and early Alzheimer disease: differentiationwith frontal lobeH-1MR spectroscopy," Radiology, vol. 203, no. 3, pp. 829-836, 1997.
23. V. Govindaraju, K. Young, and A. A. Maudsley, "Proton NMR chemical shifts and coupling constants for brain metabolites," NMR in Biomedicine, vol. 13, pp. 129-153, 2000.
24. S. R. Dager, N. M. Corrigan, T. L. Richards, and S. Posse, "Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders," Topics inMagnetic Resonance Imaging, vol. 19, no. 2, pp. 81-96, 2008.
25. D. P. Soares and M. Law, "Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications," Clinical Radiology, vol. 64, no. 1, pp. 12-21, 2009.
26. S. Minoshima, B. Giordani, S. Berent, K. A. Frey, N. L. Foster, and D. E. Kuhl, "Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease," Annals of Neurology, vol. 42, no. 1, pp. 85-94, 1997.
27. Y. Li, A. P. Chen, J. C. Crane, S. M. Chang, D. B. Vigneron, and S. J. Nelson, "Three-dimensional J-resolved H-1 magnetic resonance spectroscopic imaging of volunteers and patients with brain tumors at 3T," Magnetic Resonance in Medicine, vol. 58, no. 5, pp. 886-892, 2007.
28. M. A. Thomas, L. N. Ryner, M. P. Mehta, P. A. Turski, and J. A. Sorenson, "Localized 2D J-resolved 1H MR spectroscopy of human brain tumors in vivo," Journal of Magnetic Resonance Imaging, vol. 6, no. 3, pp. 453-459, 1996.
29. R. C. Petersen, G. E. Smith, S. C. Waring, R. J. Ivnik, E. G. Tangalos, and E. Kokmen, "Mild cognitive impairment: clinical characterization and outcome," Archives of Neurology, vol. 56, pp. 303-308, 1999.
30. M.Grundman, R. C. Petersen, S. H. Ferris et al., "Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials," Archives of Neurology, vol. 61, no. 1, pp. 59-66, 2004.
31. R. C. Petersen, R. Doody, A. Kurz, and etal, "Current concepts in mild cognitive impairment," Archives of Neurology, vol. 58, pp. 1985-1992, 2001.
32. N. A.Honeycutt, P.D. Smith, E.Aylward et al., "Mesial temporal lobe measurements on magnetic resonance imaging scans," Psychiatry Research, vol. 83, no. 2, pp. 85-94, 1998.
33. P. E. Barta, L. Dhingra, R. Royall, and E. Schwartz, "Improving sterological estimates for the volume of structures identified in three-dimensional arrays of spatial data," Journal of Neuroscience Methods, vol. 75, no. 2, pp. 111-118, 1997.
34. H. J. G. Gundersen, P. Bagger, T. F. Bendtsen et al., "The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis," APMIS, vol. 96, no. 7-12, pp. 857-881, 1988.
35. G. H. Glover, T. Q. Li, and D. Ress, "Image-based method for retrospective correction of physiological motion effects in fMRI: RETROICOR," Magnetic Resonance in Medicine, vol. 44, pp. 162-167, 2000.
36. C.C.Hanstock, D. L. Rothman, J. W. Prichard, T. Jue, and R. G. Shulman, "Spatially localized 1H NMR spectra of metabolites in the human brain," Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 6, pp. 1821-1825, 1988.
37. R. A. E. Edden, A. D. Harris, K. Murphy et al., "Edited MRS is sensitive to changes in lactate concentration during inspiratory hypoxia," Journal of Magnetic Resonance Imaging, vol. 32, no. 2, pp. 320-325, 2010.
38. N. M. Corrigan, T. L. Richards, S. D. Friedman, H. Petropoulos, and S. R. Dager, "Improving 1H MRSI measurement of cerebral lactate for clinical applications," Psychiatry Research-Neuroimaging, vol. 182, no. 1, pp. 40-47, 2010.
39. K. Blennow, "Biomarkers in Alzheimer's disease drug development," Nature Medicine, vol. 16, no. 11, pp. 1218-1222, 2010.
40. P. Chen, G. Ratcliff, S. H. Belle, J. A. Cauley, S. T. DeKosky, andM.Ganguli, "Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented," Neurology, vol. 55, no. 12, pp. 1847-1853, 2000.
41. N. Villain, B. Desgranges, F. Viader et al., "Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease," The Journal of Neuroscience, vol. 28, no. 24, pp. 6174-6181, 2008.
42. D. S. Margulies, J. L. Vincent, C. Kelly et al., "Precuneus shares intrinsic functional architecture in humans and monkeys," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 47, pp. 20069-20074, 2009.
43. C. Sorg, V. Riedl,M.Mühlau et al., "Selective changes of restingstate networks in individuals at risk for Alzheimer's disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 47, pp. 18760-18768, 2007.
44. Y. Zhou, J. H. Dougherty Jr.,K. F.Hubner, B. Bai, R. L. Cannon, and R. K. Hutson, "Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment," Alzheimer's and Dementia, vol. 4, no. 4, pp. 265-270, 2008.
45. G. Chételat, B. Desgranges, V. De la Sayette, F. Viader, F. Eustache, and J.-C. Baron, "Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?" Neurology, vol. 60, no. 8, pp. 1374-1377, 2003.
46. A. Drzezga, N. Lautenschlager, H. Siebner et al., "Cerebral metabolic changes accompanying conversion of mild cognitive impairment into alzheimer's disease: a PET follow-up study," European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 8, pp. 1104-1113, 2003.
47. C. P. Chi and E. L. Roberts Jr., "Energy substrates for neurons during neural activity: a critical review of the astrocyte-neuron lactate shuttle hypothesis," Journal of Cerebral Blood Flow and Metabolism, vol. 23, no. 11, pp. 1263-1281, 2003.
48. J. Prichard, D. Rothman, E. Novotny et al., "Lactate rise detected by 1HNMRin human visual cortex during physiologic stimulation," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 13, pp. 5829-5831, 1991.
49. L. Shalak and J.M. Perlman, "Hypoxic-ischemic brain injury in the term infant-current concepts," Early Human Development, vol. 80, no. 2, pp. 125-141, 2004.
50. P. E. Sijens, P. C. Levendag, C. J. Vecht, P. van Dijk, and M. Oudkerk, "1H MR spectroscopy detection of lipids and lactate in metastatic brain tumors,"NMR in Biomedicine, vol. 9, pp. 65-71, 1996.
51. G. Aliev, H. H. Palacios, B. Walrafen, A. E. Lipsitt, M. E. Obrenovich, and L.Morales, "Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease," International Journal of Biochemistry and Cell Biology, vol. 41, no. 10, pp. 1989-2004, 2009.
52. G. A. Dienel and N. F. Cruz, "Imaging brain activation: simple pictures of complex biology," Annals of the New York Academy of Sciences, vol. 1147, pp. 139-170, 2008.
53. D. J. Selkoe, "Alzheimer's disease is a synaptic failure," Science, vol. 298, no. 5594, pp. 789-791, 2002.
54. M. Kadekaro, A.M. Crane, and L. Sokoloff, "Differential effects of electrical stimulation of sciatic nerve onmetabolic activity in spinal cord and dorsal root ganglion in the rat," Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 17, pp. 6010-6013, 1985.
55. I. Allaman, M. Gavillet, M. Bélanger et al., "Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability," Journal of Neuroscience, vol. 30, no. 9, pp. 3326-3338, 2010.
56. D. J. Rossi, J. D. Brady, and C.Mohr, "Astrocytemetabolismand signaling during brain ischemia," Nature Neuroscience, vol. 10, no. 11, pp. 1377-1386, 2007.
57. P.Bubber, V. Haroutunian, G. Fisch, J. P. Blass, andG.E.Gibson, "Mitochondrial abnormalities in Alzheimer brain: mechanistic implications," Annals of Neurology, vol. 57, no. 5, pp. 695-703, 2005.
58. M. I. Shevell, P. M.Matthews, C. R. Scriver et al., "Cerebral dysgenesis and lactic acidemia: an MRI/MRS phenotype associated with pyruvate dehydrogenase deficiency," Pediatric Neurology, vol. 11, no. 3, pp. 224-229, 1994.
59. J. P. Blass, "A new approach to treating Alzheimer's disease," Annals of the New York Academy of Sciences, vol. 1147, pp. 122-128, 2008.